Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Queensland Health
US Army
Harvard Business School

Generated: March 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,017,512

« Back to Dashboard

Title: Radiolabeled peptides
Abstract:This invention relates to therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic agents. Specifically, the invention relates to cyclic peptide derivatives and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods and kits for making, radiolabeling and using such peptides for radiodiagnostic and radiotherapeutic purposes. The invention specifically relates to cyclic peptide derivatives and analogues of somatostatin radiolabeled with technetium-99m and uses thereof as scintigraphic imaging agents. The invention also specifically relates to cyclic peptide derivatives and analogues of somatostatin radiolabeled with cytotoxic radioisotopes such as rhenium-186 (.sup.186 Re) and rhenium-188 (.sup.188 Re) for use as radiotherapeutic agents. Methods and kits for making, radiolabeling and using such peptides diagnostically and therapeutically in a mammalian body are also provided.
Inventor(s): Dean; Richard T. (Bedford, NH), McBride; William (Summit, NJ), Lister-James; John (Bedford, NH)
Assignee: Diatide, Inc. (Londonderry, NH)
Filing Date:Sep 15, 1997
Application Number:08/931,095
Claims:1. A reagent comprising:

a) a somatostatin receptor-binding peptide having a formula:


B.sup.1 is D-Tyr or L-Tyr;

B.sup.2 is D-Trp or L-Trp;

B.sup.3 is D-Lys or L-Lys;

B.sup.4 is Val;

C.sup.4 is L-Lys;

A.sup.4 is a lipophilic L-(.alpha.-N-alkyl) amino acid;

wherein A.sup.4 and C.sup.4 are covalently linked through an amino terminus of A.sup.4 and a carboxyl terminus of C.sup.4 to form a cyclic peptide; and

b) a radiolabel-binding moiety covalently linked to C.sup.4.

2. A composition comprising a peptide having a formula selected from the group consisting of:

cyclo-(N--CH.sub.3)FYW.sub.D KV.K; and

cyclo-(N--CH.sub.3)FYW.sub.D KV.K.(BAT).

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.